|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 300.75 DKK | +0.59% |
|
-2.43% | -52.00% |
| 12-08 | Health Care Down Amid Intensified Obesity-Drug Competition - Health Care Roundup | DJ |
| 12-08 | European Equities Traded in the US as ADRs Little Changed in Monday Trading | MT |
| Capitalization | 1,329B 207B 178B 167B 155B 286B 18,634B 312B 1,946B 754B 8,798B 776B 759B 32,233B | P/E ratio 2025 * |
13x | P/E ratio 2026 * | 13x |
|---|---|---|---|---|---|
| Enterprise value | 1,433B 223B 192B 180B 167B 309B 20,097B 337B 2,099B 813B 9,489B 837B 819B 34,763B | EV / Sales 2025 * |
4.66x | EV / Sales 2026 * | 4.67x |
| Free-Float |
70.25% | Yield 2025 * |
3.89% | Yield 2026 * | 3.82% |
Last Transcript: Novo Nordisk A/S
| 1 day | +0.54% | ||
| 1 week | -2.43% | ||
| Current month | -5.49% | ||
| 1 month | +1.66% | ||
| 3 months | -11.54% | ||
| 6 months | -42.36% | ||
| Current year | -52.00% |
| 1 week | 297.55 |  | 315.1 |
| 1 month | 266.9 | | 326.4 |
| Current year | 266.9 | | 675.2 |
| 1 year | 266.9 | | 798.1 |
| 3 years | 266.9 | | 1,033.2 |
| 5 years | 208.78 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 06/08/2025 | |
| Director of Finance/CFO | 54 | 14/02/2018 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 55 | 06/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 60 | 22/03/2017 |
| Director/Board Member | 50 | 21/03/2018 | |
Thomas Rantzau
BRD | Director/Board Member | 53 | 21/03/2018 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 21.31% | 1,412 M€ | +0.04% | - |
| 10.45% | 4 M€ | +20.58% | - |
| 5.4% | 26 M€ | +11.55% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.59% | -2.43% | -61.70% | -34.99% | 207B | |
| -1.26% | -5.70% | +20.67% | +168.32% | 893B | |
| -0.15% | -1.81% | +35.03% | +13.78% | 486B | |
| -1.31% | -0.88% | +26.64% | +34.42% | 394B | |
| +0.03% | +1.28% | +23.37% | +4.17% | 336B | |
| +0.96% | -0.36% | +28.48% | +21.10% | 280B | |
| -0.24% | +0.24% | +19.11% | +24.54% | 253B | |
| -0.79% | -2.85% | -4.04% | -10.75% | 246B | |
| -2.63% | -4.82% | +17.85% | +12.49% | 173B | |
| -0.02% | -2.53% | +31.54% | +35.45% | 150B | |
| Average | -0.51% | -2.03% | +13.69% | +26.85% | 341.87B | |
| Weighted average by Cap. | -0.63% | -2.41% | +17.77% | +53.17% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 308B 47.86B 41.2B 38.68B 35.95B 66.27B 4,315B 72.3B 451B 175B 2,037B 180B 176B 7,464B | 306B 47.61B 40.98B 38.47B 35.76B 65.92B 4,292B 71.91B 448B 174B 2,026B 179B 175B 7,424B |
| Net income | 103B 15.98B 13.76B 12.91B 12.01B 22.13B 1,441B 24.14B 150B 58.28B 680B 59.98B 58.7B 2,492B | 100B 15.59B 13.42B 12.6B 11.71B 21.58B 1,405B 23.55B 147B 56.84B 664B 58.5B 57.25B 2,431B |
| Net Debt | 104B 16.22B 13.97B 13.11B 12.19B 22.46B 1,463B 24.51B 153B 59.16B 691B 60.89B 59.59B 2,530B | 99.59B 15.49B 13.34B 12.52B 11.64B 21.45B 1,397B 23.41B 146B 56.5B 660B 58.15B 56.91B 2,416B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/25 | 299.60 kr | +0.20% | 503,780 |
| 08/12/25 | 299.00 kr | -3.42% | 5,643,749 |
| 05/12/25 | 309.60 kr | +1.24% | 5,369,194 |
| 04/12/25 | 305.80 kr | +0.66% | 6,173,721 |
| 03/12/25 | 303.80 kr | -1.06% | 4,265,824 |
Delayed Quote Nasdaq Copenhagen, December 09, 2025 at 08:37 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition